Search filters

Filters
Clear All

Phase

  • 4
  • 3
  • 6
  • 7
  • 1
  • 33
  • 56
  • 31
  • 1
  • 55

Found 56 Lung Disease trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Supporting Evidence-based Responses to Emotional Needs in Emphysema
18 - 100
All genders
Families play an important role in the experiences of patients with chronic illnesses, including chronic obstructive pulmonary disease (COPD). This study aims to identify how an evidence-based coping skills training program, where patients and a support person work together to manage and overcome disease-related distress, can reduce depression and anxiety …
99 or below
All genders
Phase 3
Low-dose computed tomography (LDCT) screening reduces mortality among current and former smokers at high risk for lung cancer, and is widely recommended by national guidelines. LDCT also increases access to care and thus provides an opportunity to deliver smoking cessation interventions to current smokers in conjunction with this screening. As …
18 - 99
All genders
Interventional
The purpose of this study is to learn about the effects of a study drug, Epetraborole, to assess the efficacy for treating refractory MAC. It will enroll patients over 18 years of age and will include the following: physical exams, CTs, medical history, ECGs, lung function tests, vital signs, safety …
99 or below
All genders
Phase 3
Systemic sclerosis is a rare chronic autoimmune connective tissue disease. B cells have been reported to play a central role in the pathogenesis of SSc and B cell depletion has been shown to offer benefit to patients with SSc. Belimumab is a monoclonal antibody, which inhibits the survival of B …
18 - 99
All genders
A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer.
99 or below
All genders
The primary objective of the study is to evaluate the safety and effectiveness of the NEUWAVETM FLEX MC Microwave Ablation System and Accessories used in transbronchial ablation procedures for adult subjects with oligometastatic tumors ( 2cm) in the lung. Technique Efficacy: Ablation of the target tumor(s) with the ablation zone …
 A Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 - 99
All genders
Phase 2
Interventional
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-0482, MK-5890, MK-4830) in combination with pembrolizumab based therapy in patients with PD-(L)1 refractory NSCLC in a rolling-arm design
 Cystic Fibrosis Microbiome
18 - 99
All genders
Among lung transplant recipients who survive to 5 years, half suffer from chronic lung allograft dysfunction (CLAD). This study will evaluate how changes in the lung microbiome may cause CLAD in Cystic Fibrosis patients who have been transplanted. This is a case-control study of Cystic Fibrosis lung transplant recipients to …
 A Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
18 - 99
All genders
Phase 2
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
99 or below
All genders
Phase 1
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
1 - 10 of 56